A read has identified genes which cooperate with a tumour suppressor gene entitled PTEN.
Experts said the finding could help treat the cancers and better identify other genes which could suppress cancer swelling.
Prostate cancer is the second most common cancer in men in the UK with all 47,000 men diagnosed each year.
More than half of prostate cancers be struck by an altered or missing PTEN gene, as do many other cancers, numbering brain tumours, and endometrial cancers.
Tumour suppressor genes such as PTEN employees prevent cancer development in healthy people.
PTEN regulates the increase of cells. However, experts said little is known about which other genes and pathways lend a hand with PTEN to prevent cancer.
In the study, researchers designed a new method in mice in which in some measure of the PTEN gene was converted a transposon — a form of DNA.
Dr Jorge de la Rosa, prime mover of the study, from the Wellcome Trust Sanger Institute, said: “We originated a new method that coupled PTEN inactivation with mobilisation of the transposon.
“By criticizing which genes were disrupted in the cancers that grew, we were skilled to pinpoint genes that cooperate with PTEN in suppressing malignancies.”
The researchers analysed 278 prostate, breast and skin tumours from the mice and revealed hundreds of genes that could collaborate with PTEN and act as tumour suppressor genes.
Human cell orders and data from human prostate tumours were then inured to to study the five most promising genes.
Dr Juan Cadiñanos, connection lead author from the Instituto de Medicina Oncologica y Molecular de Asturias, in Spain, state: “This is the first study to look specifically for tumour suppressor genes that in concert with PTEN in a range of cancer types.
“We found that genetically inactivating PTEN and each of the five runner genes in human cell lines did drive cancerous changes in the rooms.
“We also discovered that human prostate cancer samples had modulate levels of expression from the five genes than usual, signifying that these pathways may be important for suppressing tumours.”
The researchers also premeditated one of the five genes, called Wac, in transgenic mice with mutant PTEN.
They noticed that removing one copy of Wac increased the size of prostate tumours. Manner, removing both copies in the genome surprisingly reduced the size of the sarcomas.
Experts said this could reveal new pathways to target for probe prostate cancer.
Professor Allan Bradley, joint lead founder from the Sanger Institute, said: “Drugs that target PTEN interconnected pathways are under development, but tumours quickly develop resistance.
“It wish therefore be useful to also target other tumour suppressor pathways.
“This new method is a adept way of highlighting important tumour suppressor networks, and we hope the genes categorized in this study will provide a basis for the development of therapeutic designs for prostate and other cancers.”
The research was reported in the journal Nature Genetics.